safety of glp 1 receptor agonists Efficacy and LY3298176, a novel dual GIP and GLP-1 agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Pharmacological interventions for obesity in

Higher efficacy Aside from pricing competition and label expansion, greater efficacy in HbA1c reduction and/or weight loss, reduced side-effects and increased patient convenience (eg an oral tablet rather than a subcutaneous injection) will also contribute to the success of new GLP-1s and associated weight loss medication

E.DierckxR

Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage

For all their promise, GLP-1 and dual GIP/GLP-1 receptor agonists have raised more questions, particularly regarding their long-term safety implications

The trim-and-fill method [21] was used to estimate the effect of publication bias, if any